Categories
Prostate cancer

High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals

  • Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9–12.

    PubMed 
    Article 

    Google Scholar
     

  • Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001;61:4315–9.

    CAS 
    PubMed 

    Google Scholar
     

  • Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–25.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • De Bono JS, Chowdhury S, Feyerabend S, Elliott T, Grande E, Melhem-Bertrandt A, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥ 24 weeks in Europe. Eur Urol. 2018;74:37–45.

    PubMed 
    Article 
    CAS 

    Google Scholar
     

  • Armstrong AJ, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl J Med. 2014;371:1028–38.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018;19:76–86.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle. 2007;6:647–51.

    Article 

    Google Scholar
     

  • Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42:668–75.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S. Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res. 2011;17:3858–64.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Chen W, Beck I, Schober W, Brockow K, Effner R, Buters JT, et al. Human mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp Dermatol. 2010;19:302–4.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, et al. Localization of androgen receptor expression in human bone marrow. J Pathol. 2001;193:361–6.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Viselli SM, Reese KR, Fan J, Kovacs WJ, Qlsen NJ. Androgens alter B cell development in normal male mice. Cell Immunol. 1997;182:99–104.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Pu Y, Xu M, Liang Y, Yang K, Guo Y, Yang X, et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci Transl Med. 2016;8:333ra47.

    PubMed 
    Article 
    CAS 

    Google Scholar
     

  • Seki T, Shimizu Y, Ishii K, Takahama Y, Kato K, Yano TNK. cells can preferentially target prostate cancer stem-like cells via the TRAIL/DR5 signalling pathway. Biomolecules. 2021;11:1702.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Kaja S, Payne AJ, Singh T, Ghuman JK, Sieck EG, Koulen P. An optimized lactate dehydrogenase release assay for screening of drug candidates in neuroscience. J Pharm Toxicol Methods. 2015;73:1–6.

    CAS 
    Article 

    Google Scholar
     

  • Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128:4654–68.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Han D, Li J, Wang H, Su X, Hou J, Gu Y, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66:1151–64.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Zhang C, Xiong J, Yang Q, Wang Y, Shi H, Tian Q, et al. Profiling and bioinformatics analyses of differential circular RNA expression in prostate cancer cells. Future Sci OA. 2018;4:FSOA340.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44–49.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79:2320–8.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88:577–83.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Antognelli C, Mandarano M, Prosperi E, Sidoni A, Talesa VN. Glyoxalase-1-dependent methylglyoxal depletion sustains PD-L1 expression in metastatic prostate cancer cells: a novel mechanism in cancer immunosurveillance escape and a potential novel target to overcome PD-L1 blockade resistance. Cancers (Basel). 2021;13:2965.

    CAS 
    Article 

    Google Scholar
     

  • Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24:1178–91.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, et al. A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer. Clin Cancer Res. 2019;25:3026–34.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH. Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol. 2016;38:52–58.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao ST. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005;65:2082–4.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 1998;12:941–53.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Pope HG, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry. 2000;57:133–40. discussion 155-156

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016;355:i4405.

    PubMed 
    Article 

    Google Scholar
     

  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl J Med. 2012;366:2443–2254.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7:52810–7.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–1.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Xia Q, Ding T, Zhang G, Li Z, Zeng L, Zhu Y, et al. Circular RNA expression profiling identifies prostate cancer- specific circRNAs in prostate cancer. Cell Physiol Biochem. 2018;50:1903–15.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Kong Z, Wan X, Zhang Y, Zhang P, Zhang Y, Zhang X, et al. Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2017;493:1217–23.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Chen KC, Chen PH, Ho KH, Shih CM, Chou CM, Cheng CH, et al. IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/beta-catenin pathway. PLoS One. 2019;14:e0225913.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Kanwal R, Plaga AR, Liu XQ, Shukla GC, Gupta S. MicroRNAs in prostate cancer: functional role as biomarkers. Cancer Lett. 2017;407:9–20.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, et al. The potential of MicroRNAs as prostate cancer biomarkers. Eur Urol. 2016;70:312–22.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Muti P, Donzelli S, Sacconi A, Hossain A, Ganci F, Frixa T, et al. MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study. Carcinogenesis. 2018;39:98–108.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Dai N, Qing Y, Cun Y, Zhong Z, Li C, Zhang S, et al. miR-513a-5p regulates radiosensitivity of osteosarcoma by targeting human apurinic/apyrimidinic endonuclease. Oncotarget. 2018;9:25414–26.

    PubMed 
    Article 

    Google Scholar
     

  • Leave a Reply